시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 혈관운동성 갱년기 증상(VMS) 치료 시장 보고서(2025년)
Vasomotor Menopausal Symptoms (VMS) Treatment Global Market Report 2025
상품코드 : 1695238
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 200 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,301,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,108,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,914,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

혈관운동성 갱년기 증상(VMS) 치료 시장 규모는 향후 몇 년 동안 강력한 성장세를 보이며 2029년까지 연평균 6.6%의 CAGR로 248억 1,000만 달러에 달할 것으로 예상됩니다. 예측 기간의 성장은 맞춤형 의료, 비호르몬 혁신, 영양 및 식이 중재, 원격의료, 디지털 건강 등에 기인할 것으로 보입니다. 예측 기간의 주요 동향으로는 자연요법 및 대체요법, 식물요법 및 허브요법, 갱년기 지원 그룹, 인지행동치료(cbt) 등이 있습니다.

혈관운동성 갱년기 증상 치료 시장의 확대는 갱년기 인구의 증가에 의해 촉진되고 있습니다. 갱년기는 여성의 생식 연령이 끝나는 자연적인 생물학적 단계로 보통 45-55세 사이에 발생하며, 평균 연령은 51세 전후입니다. 전 세계적으로 안면홍조, 질 건조증 등의 증상 치료를 원하는 갱년기 여성들이 증가하고 있는 것이 혈관운동성 갱년기(VMS) 치료제의 성장을 촉진하는 중요한 요인으로 작용하고 있습니다. 예를 들어, 미국 Cuyuna Regional Medical Center의 데이터에 따르면, 평균 수명의 증가로 인해 2025년까지 11억 명의 여성이 폐경기를 맞이할 것으로 추정됩니다. 또한, 폐경기 인구는 2060년까지 매년 1.6%씩 증가할 것으로 예측됩니다. 따라서 갱년기 인구층의 확대가 혈관운동성 갱년기 증상 치료 시장의 성장 원동력이 되고 있습니다.

갱년기 여성의 건강에 초점을 맞춘 정부의 노력은 혈관운동성 갱년기 증상 치료 시장의 성장을 촉진할 것입니다. 이러한 노력에는 폐경기의 다양한 측면에 대한 혁신적인 연구, 질병 예방, 약리학, 임상 및 역학 조사에 대한 자금 지원이 포함됩니다. 이러한 노력은 광범위한 관심사를 다루는 광범위한 여성 건강 이니셔티브의 일환입니다. 예를 들어, 호주 뉴사우스웨일즈 주 정부는 폐경기 증상을 겪는 여성들을 지원하기 위해 최대 16개의 새로운 프로그램을 신설하기 위해 4년간(2022-2023-2025-2026년) 4,030만 달러를 할당하고 있습니다. 따라서 갱년기 여성 건강에 초점을 맞춘 이러한 정부의 노력은 혈관운동성 갱년기 증상 치료 시장의 성장을 촉진하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

ksm
영문 목차

영문목차

Vasomotor menopausal symptoms (VMS) treatment involves medical interventions and therapies aimed at alleviating or managing the range of symptoms associated with menopause. These symptoms, experienced by women during menopause, include hot flashes and night sweats. The treatment approach focuses on rebalancing hormone levels in the body and modifying neurotransmitters in the brain.

The primary categories of medications used in vasomotor menopausal symptoms (VMS) treatment include antidepressants like fluoxetine, paroxetine, and sertraline, hormone therapy, anticonvulsants such as phenytoin and phenobarbital, and others. Antidepressants constitute a class of drugs primarily prescribed to address depression and certain other mental health conditions. These medications are available through various distribution channels, including hospital pharmacies, online pharmacies, and retail pharmacies, catering to different end-users such as hospitals, specialty clinics, and homecare settings.

The vasomotor menopausal symptoms (VMS) treatment market research report is one of a series of new reports from The Business Research Company that provides vasomotor menopausal symptoms (VMS) treatment market statistics, including vasomotor menopausal symptoms (VMS) treatment industry global market size, regional shares, competitors with a vasomotor menopausal symptoms (VMS) treatment market share, detailed vasomotor menopausal symptoms (VMS) treatment market segments, market trends and opportunities and any further data you may need to thrive in the vasomotor menopausal symptoms (VMS) treatment industry. This vasomotor menopausal symptoms (VMS) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vasomotor menopausal symptoms (VMS) treatment market size has grown strongly in recent years. It will grow from $17.86 billion in 2024 to $19.19 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to hormone replacement therapy (hrt), menopause awareness, pharmaceutical developments, consumer demand.

The vasomotor menopausal symptoms (VMS) treatment market size is expected to see strong growth in the next few years. It will grow to $24.81 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to personalized medicine, non-hormonal innovations, nutritional and dietary interventions, telemedicine and digital health. Major trends in the forecast period include natural and alternative approaches, botanical and herbal remedies, menopause support groups, cognitive behavioral therapy (cbt).

The expansion of the vasomotor menopausal symptoms treatment market is fueled by the increasing menopausal population. Menopause, a natural biological phase signifying the end of a woman's reproductive years, typically occurs between the ages of 45 and 55, with an average age of around 51. The growing number of menopausal women worldwide seeking treatment for symptoms like hot flashes and vaginal dryness is a key factor propelling the growth of treatments for vasomotor menopausal symptoms (VMS). For example, data from the Cuyuna Regional Medical Center, a U.S.-based organization, indicates that due to increased life expectancy, an estimated 1.1 billion women will reach menopause by 2025. Additionally, the menopausal population is projected to grow by 1.6% annually until 2060. Hence, the expanding menopausal demographic is a driving force behind the vasomotor menopausal symptoms treatment market's growth.

Government initiatives focused on women's health during menopause are set to drive the growth of the vasomotor menopausal symptoms treatment market. These initiatives encompass funding for innovative research on various aspects of the menopausal transition, disease prevention, and pharmacological, clinical, and epidemiological investigations. Such efforts are part of broader women's health initiatives that address a wide range of concerns. As an illustration, the Government of New South Wales, an Australia-based government agency, has allocated $40.3 million over four years (from 2022-2023 to 2025-2026) to establish up to 16 new programs aimed at assisting women experiencing severe menopausal symptoms. Therefore, these government initiatives focusing on women's health during menopause are propelling the growth of the market for vasomotor menopausal symptoms treatment.

Prominent companies engaged in the vasomotor menopausal symptoms treatment market are prioritizing the development of products like Veozah and securing approvals to offer new treatment alternatives that address unmet medical requirements for patients. The approval of novel drugs for menopausal symptom management presents advantages in terms of improved efficacy and safety compared to existing treatments. For example, in May 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, received FDA approval for Veozah (fezolinetant) 45 mg, designed to be taken once daily, for the treatment of menopausal vasomotor symptoms (VMS), spanning from mild to severe. Veozah is the first nonhormonal neurokinin 3 (NK3) receptor antagonist authorized for managing menopausal-related VMS. This hormone-free option functions by blocking a neural pathway involved in regulating these symptoms. Veozah provides an alternative treatment choice, particularly for women experiencing such symptoms who either cannot or prefer not to use hormone therapy. The approval of Veozah underscores its potential as a novel drug for addressing menopausal symptoms.

In March 2022, Amyris Inc., a U.S.-based biotechnology firm, acquired MenoLabs LLC for $35.4 million. This acquisition enables Amyris to broaden its presence in the women's health market, gain access to new technologies and capabilities, and acquire a dedicated customer base. MenoLabs LLC, a U.S.-based women's health and technology company, specializes in the development of dietary supplements designed to alleviate menopause symptoms in women.

Major companies operating in the vasomotor menopausal symptoms (vms) treatment market are Pfizer Inc., Abbvie Inc., Novartis AG, Ausio Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Alembic Pharmaceuticals Limited Inc., Apotex Inc., Hikma Pharmaceutical PLC, Endo Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Mundipharma International Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Zhejiang Huahai Pharmaceutical Co. Ltd., Emcure Pharmaceuticals Limited, Wockhardt Pvt. Ltd., QuatRx Pharmaceuticals Company, Bionovo Inc., Mithra Pharmaceuticals SA, EndoCeutics Inc., Zydus Group, Edgemont Pharmaceuticals LLC, MenoGeniX Inc., Agile Therapeutics Inc.

North America was the largest region in the vasomotor menopausal symptoms (VMS) treatment market in 2024. The regions covered in vasomotor menopausal symptoms (VMS) treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vasomotor menopausal symptoms (VMS) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vasomotor menopausal symptoms (VMS) treatment market consists of revenues earned by entities by providing services such as cognitive-behavioral therapy, acupuncture, lifestyle modifications, herbal and vitamin supplements and complementary and alternative therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The vasomotor menopausal symptoms (VMS) treatment market also includes sales of natural supplements, cooling products, vaginal estrogen products, stress-reduction products, sleep aids and dietary supplements. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vasomotor Menopausal Symptoms (VMS) Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vasomotor menopausal symptoms (vms) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for vasomotor menopausal symptoms (vms) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vasomotor menopausal symptoms (vms) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Vasomotor Menopausal Symptoms (VMS) Treatment Market Characteristics

3. Vasomotor Menopausal Symptoms (VMS) Treatment Market Trends And Strategies

4. Vasomotor Menopausal Symptoms (VMS) Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Vasomotor Menopausal Symptoms (VMS) Treatment Growth Analysis And Strategic Analysis Framework

6. Vasomotor Menopausal Symptoms (VMS) Treatment Market Segmentation

7. Vasomotor Menopausal Symptoms (VMS) Treatment Market Regional And Country Analysis

8. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market

9. China Vasomotor Menopausal Symptoms (VMS) Treatment Market

10. India Vasomotor Menopausal Symptoms (VMS) Treatment Market

11. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market

12. Australia Vasomotor Menopausal Symptoms (VMS) Treatment Market

13. Indonesia Vasomotor Menopausal Symptoms (VMS) Treatment Market

14. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market

15. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market

16. UK Vasomotor Menopausal Symptoms (VMS) Treatment Market

17. Germany Vasomotor Menopausal Symptoms (VMS) Treatment Market

18. France Vasomotor Menopausal Symptoms (VMS) Treatment Market

19. Italy Vasomotor Menopausal Symptoms (VMS) Treatment Market

20. Spain Vasomotor Menopausal Symptoms (VMS) Treatment Market

21. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market

22. Russia Vasomotor Menopausal Symptoms (VMS) Treatment Market

23. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market

24. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market

25. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market

26. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market

27. Brazil Vasomotor Menopausal Symptoms (VMS) Treatment Market

28. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market

29. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market

30. Vasomotor Menopausal Symptoms (VMS) Treatment Market Competitive Landscape And Company Profiles

31. Vasomotor Menopausal Symptoms (VMS) Treatment Market Other Major And Innovative Companies

32. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Vasomotor Menopausal Symptoms (VMS) Treatment Market

34. Recent Developments In The Vasomotor Menopausal Symptoms (VMS) Treatment Market

35. Vasomotor Menopausal Symptoms (VMS) Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기